Searchable abstracts of presentations at key conferences in endocrinology

ea0074ncc29 | Highlighted Cases | SFENCC2021

A triumvirate of macroprolactinoma, apoplexy and aneurysm: what is the optimal management strategy?

Mathara Diddhenipothage Shani Apsara Dilrukshi , Anguelova Lia , Amarouche Meriem , May Christine , Jafar-Mohammadi Bahram , Joseph Robin , Cudlip Simon , Pal Aparna

Case history: A 57-year-old male with well controlled primary hypertension presented with acute onset severe headache while exercising, associated with nausea and vomiting. He had no visual or other neurological symptoms. The pain settled with analgesics in ED. He reported four transient similar episodes during the preceding 18 months. There were no symptoms suggestive of pituitary or other endocrine dysfunction, including hyperprolactinaemia. Clinical examination was unremark...

ea0099p92 | Endocrine-Related Cancer | ECE2024

How well does ‘real world’ management of Immune check point inhibitor induced hypophysits (ICI-Hp) reflect the European Society of Endocrinology (ESE) 2023 clinical practice guidelines (CPG)?: Experience from a single tertiary care centre

Mathara Diddhenipothage Shani Apsara Dilrukshi , Warden Jacqui , Herbert Katie , Pofi Riccardo , Coupe Nicholas , Payne Miranda , Tomlinson Jeremy W , Turner Helen

Introduction: Hypophysitis (Hp) is a serious adverse effect (AE) of Immune check-point inhibitor (ICI) therapy in malignancy. We evaluated 6 yeas of clinical expereince with ICI against the recent ESE CPG 2023 which provides practical guidance on the management of this condition based on up-to-date evidence.Methods: A quality improvement project (QIP) included all patients with ICI-Hp (n=17) referred to a dedicated Endocrine-ICI clinic (January ...